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Adult T-cell leukemia (ATL) is an aggressive CD4+ T-cell
malignancy caused by the oncogenic retrovirus human T-cell
leukemia virus-1 (HTLV-1).1 Although the cumulative incidence of
ATL among HTLV-1-infected individuals is only 5%, it has an
extremely poor prognosis and remains a major health concern in
endemic regions.2,3 Patients with an aggressive subtype have a
median survival of 4–6 and 9–10 months for acute and lymphoma
subtypes, respectively (Shimoyama classiﬁcation4). Indolent forms
(chronic and smoldering) have a more favorable median survival
of 33 and 51 months. Treatment strategies for ATL mainly depend
on clinical subtype, geographical localization and response to
initial therapy.5,6 In Japan, aggressive forms are treated by
conventional chemotherapy combined or not with allogeneic
stem cell transplantation,7 while in western countries the
combination of zidovudine (AZT) with interferon (IFN) alpha is
the standard ﬁrst-line therapy for acute leukemic subtypes and
chronic forms.6 Response to treatment and complete clinical
remission are currently deﬁned on the basis of cytomorphological
consensus criteria that have not been revised over the 8 years
since they were ﬁrst described8 (Supplementary Methods). Given
the extremely poor prognosis of ATL, the high rates of rapid
relapse and the marked diversity in survival outcome after
achieving hematological remission, there is an urgent need for
new molecular tools that can reliably evaluate therapeutic
response and better deﬁne remission.
The development of ATL is associated with the emergence of a
dominant clone uniquely identiﬁed by the proviral integration site
within the host genome, with an underlying polyclonal population
of infected cells of varying abundance.9,10 In the majority of ATL
cases examined to date, the presumed malignant clone carries a
single proviral integration.9–11 In this study, we explored the
beneﬁt of an optimized high-throughput sequencing (HTS)
clonality method as a quantitative molecular approach to monitor
the malignant clone identiﬁed at diagnosis and better evaluate
therapeutic response.10,12 The method enables the genome-wide
mapping of HTLV-1 integration sites and the simultaneous
quantiﬁcation of the abundance of the corresponding clones. It
includes several critical modiﬁcations that overcome the limita-
tions of previously reported protocols,13,14 increasing sensitivity,
facilitating multiplexing, and signiﬁcantly reducing both the cost
and hands-on time (Supplementary Methods). As a proof-of-
concept, we analyzed retrospective longitudinal samples of ﬁve
ATL patients diagnosed with a leukemic subtype who all achieved
complete hematological remission upon induction therapy.
Although all ﬁve patients eventually relapsed, the duration of
hematological remission and the clinical course were variable
between patients (Supplementary Table 1). Two patients achieved
a protracted clinical remission of 5.8 and 2.4 years (ATL11 and
ATL60; Figures 1a and b), while three patients relapsed after a
signiﬁcantly shorter remission of 4.3, 5.3 and 3.7 months for ATL7,
ATL14 and ATL100, respectively (Table 1, Figures 1c–e).
For each ATL patient, we analyzed the clonal architecture (i) at
diagnosis, (ii) at relapse and (iii) at intermediate time points that
consisted of either a single (CR1; ATL7 and ATL100) or multiple
(CR1, CR2, CR3; ATL11, ATL14 and ATL60) longitudinal samples
collected at hematological remission. PVL (proviral copies per 100
peripheral blood mononuclear cells), T-cell receptor (TCR)-γ
rearrangement and blood immuno-phenotypes were also
recorded (Table 1). HTS mapping of HTLV-1 integration sites at
diagnosis revealed a single dominant integration site that
constituted 92.75 to 99.86% (mean 95.9%) of proviral genomes
in four ATL cases (ATL7, ATL11, ATL14 and ATL100). In the
remaining tumor (ATL60), there was evidence of four dominant
proviruses present at the same frequency in a single malignant
clone, consistent with the observation of a single TCR-γ
rearrangement (total relative abundance 99.05%). All patients
were treated and achieved complete clinical remission
(Supplementary Table 1 and Supplementary Methods). For 2/5
patients, molecular analysis revealed that the predominant HTLV-1
insertion site of the presumed malignant clone fell from 97.32 to
1.87% (ATL11) and from 99.05 to 2.15% (ATL60) following
treatment. In both patients, the clone frequency distribution of
HTLV-1-infected cells at clinical remission was composed of
multiple low abundance clones, of which the unique presumed
malignant integration site contributed to o3% of proviral
genomes (Figures 1a and b, CR1). One patient (ATL11) remained
in clinical and molecular remission for 5 years and 11 months with
no signiﬁcant change in clone frequency and modest ﬂuctuations
in PVL (CR2 and CR3; Figure 1a), while the second patient (ATL60)
showed a gradual yet moderate recurrence of the malignant clone
over the 2 year and 4 month period of complete hematological
remission with no increase in PVL (9.25 and 36.95%, CR2 and CR3,
Figure 1b). Clonality analysis of ATL60 at relapse revealed the full
recurrence of the predominant integration sites detected at
diagnosis with clonal abundance of 99.46%. ATL11 relapsed with a
lymphoma subtype and a different clone (89.3% abundance),
consistent with previous reports of clonal transition during the
clinical course of ATL.15 The dominant integration site was
supported by 3′ long terminal repeat (LTR)–host junctions yet 5′
LTR-dependent reads were not retrieved in the sequencing
output, strongly suggesting that the new malignant clone that
emerged at relapse carried a 5′LTR-deleted provirus. We veriﬁed
that this was the case by applying the long-range Oxford
Nanopore sequencing technology to characterize the provirus
and its genomic boundaries in the lymphoma that developed at
relapse (Supplementary Figure 1). This demonstrated the ability of
our 5′/3′ dual HTS approach in faithfully identifying 5′LTR-deleted
type 2-defective proviruses that have been observed in one-third
of ATLs and have prognostic value.9–11 Clonality analysis of the
remaining 3/5 patients after induction therapy revealed that,
contrary to ATL11 and ATL60, the relative abundance of the
malignant clone identiﬁed at diagnosis remained dominant at
clinical remission (73.4, 43.24 and 55.43% at CR1; 92.75, 99.86 and
94.95% at diagnosis for ATL7, ATL14 and ATL100, respectively)
while the clinical response criteria were consistent with complete
hematological remission and the PVLs had decreased 1.7–41000-
fold (Table 1 and Figures 1c–e). These patients relapsed after 4.3,
5.3 and 3.7 months, respectively, with the dominant malignant
clone 486% (86.20, 88.1, and 99.12%, respectively). Thus the
molecular follow-up of these patients revealed refractoriness to
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ﬁrst-line therapy at time points where clinical response criteria
indicated complete hematological remission. Interestingly, while
lymphocyte counts and blood smears remained unremarkable
during complete remission in ATL14 (Table 1), longitudinal HTS
revealed molecular recurrence of the malignant clone at these
time points (abundance of 43.24–70.84%, CR1 and CR3). This
Figure 1. For caption see next page.
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patient relapsed with strong lymph node involvement (LN++), yet
blood parameters remained in the normal range. This demon-
strates that HTS analysis of the blood of a patient in complete
hematological remission can predict relapse at distant sites.
We also analyzed TCR-γ rearrangement and ﬂow cytometry
(FCM) immuno-phenotype proﬁles for all samples (Figure 1 and
Table 1). These assays appeared to be better indicators of
recurrence than the standard hematological response criteria at
certain time points, yet both had their limitations. With regards to
TCR-γ, HTS clonality was a superior predictor of refractoriness to
induction therapy (Figure 1, ATL100 CR1, ATL14 CR1 and CR2). It
also enabled the quantitative assessment of recurrence after a
short period of molecular remission (Figure 1, ATL60) and showed
increased sensitivity (Figure 1d, CR1, 0.007% absolute abundance
versus ~ 1% sensitivity for TCR-γ assay). FCM revealed an abnormal
lymphocyte population that expressed CD4+/CD25+/CD7−/CD3dim
in 4/5 ATLs; however, the interpretation of FCM proﬁles for
accurate detection of residual disease based on CD3dim status
remained problematic given the overlap of CD3 levels with the
distribution observed in healthy individuals. Furthermore, not all
ATL cases show CD3dim phenotypes (Table 1, ATL100: CD3high),
demonstrating the limitations of FCM as a marker of molecular
response. Finally, RNA-seq of ATLs at diagnosis and relapse
revealed the consistent production of HBZ antisense transcripts
while 5′LTR-dependent sense transcription— including Tax—was
undetectable, consistent with previously published studies of our
group and others.10,11 As expected, we did not observe signiﬁcant
differences in HBZ levels between diagnosis and relapse
(P= 0.3946, Table 1, Supplementary Table 2). Altogether, these
observations support the conclusion that the HTS clonality
method is superior to any other assay tested thus far.
In summary, this pilot study shows that molecular knowledge
with regards to HTLV-1 clonal architecture and follow-up of the
dominant leukemic clone over time enable a more reliable deﬁnition
of remission and a better estimate of molecular response in ATL
patients. HTS can reveal ATLs refractory to ﬁrst-line therapy or detect
molecular relapse in patients that achieve hematological remission.
Additionally, the method can identify 5′LTR-variants, clone switch
Table 1. Patients’ clinical and molecular characteristics
Patient Status ALC (G/l) Blood smear ATL localization Calcemia (mmol/l) LDH TCR FCM % CD4/CD8% HBZ PVL %
ATL7 D 43.9 45% Blood, LN 2.38 4N + 480 2.43/3.28 × 83
CR1 1.3 — 2.21 1.5N + 25 24.1/12.7 47
R 3.5 45% Blood, CNS 2.26 7N + 50 11.7/8.1 × 78
ATL11 D 1.3 45% Blood 2.27 o1N + 40 37.7/9.5 × 33
CR1 2.1 o5% 2.31 1.5N − 4 14.50/44.5 24
CR2 1.4 — 2.32 o1N − o5 23.3/25.6 18
CR3 1.6 — ND o1N − 4 34.2/16.1 48
R 1.8 o5% LN 2.49 2N −
Lymphoma +a 6 27.1/17.6 52
ATL14 D 16.4 45% Blood, LN 2.17 17N + 85 2.5/2.0 × 265
CR1 0.2 — 2.3 6N − 0.20 8.0/11.0 0.016
CR2 0.6 — 2.4 1.5N − 6 12.3/27.3 14
CR3 1.2 — 2.46 1.5N + 10 15.6/21.8 11
R 1.9 45% Blood, LN++ 2.5 ND + 14 18.2/19.6 × 40
ATL60 D 7.8 45% Blood, LN 2.97 5N + 450 6.4/21.3 × 510
CR1 1.3 — 2.36 2N − o1 13.4/28.7 1
CR2 2.8 — 2.31 1.5N + 4 18.4/53.7 8
CR3 2.6 — Normal 1.5N + 6 16.6/56.3 4
R 47.2 45% Blood 3.7 6N + 78 2.7/11.5 × 526
ATL100 D 8.0 45% Blood, liver Normal 6N + 470b 3.8/3.7 106
CR1 3.2 — Normal 1.5N − 3b 15.7/17.3 8
R 12.4 45% Blood, liver Normal 5N + 495b 1.3/1.3 × 102
Abbreviations: ALC, absolute lymphocyte count; ATL11 D: corresponds to the earliest available sample from this patient (non-responder clinical status after
chemotherapy, prior to AZT-IFN alpha-As203 treatment); Blood smear, the presence of ﬂower cells (%); CD4/CD8, percentage CD4
+ and CD8+ lymphocytes
determined by FCM; CR, complete remission; D, diagnosis; FCM, percentage CD4+/CD25+/HLADR+/CD7−/CD3dim lymphocytes in PBMCs determined by ﬂow
cytometry immuno-phenotyping; HBZ, indicates ATLs at diagnosis and relapse for which HBZ transcripts were quantiﬁed by RNA-seq; there was no signiﬁcant
difference in the HBZ expression levels between D and R (P = 0.3946, global analysis combining this data set and a previously published ATL data set,10
Supplementary Table 2 and Supplementary Methods); LHD, lactate dehydrogenase; N, normal values; ND, not done or not available; PVL, proviral load in
copies of tax per 100 PBMCs; R, relapse; TCR, clonal TCR-γ rearrangement in the blood. aTCR-γ rearrangement in lymphoma, distinct clone. bATL100
characterized by CD4+/CD25+/HLA DR+/CD7−/CD3high cell population.
Figure 1. Longitudinal monitoring of the dominant malignant clone and clone frequency distribution in ﬁve ATL patients. (a–e) Evolution of
the abundance of the dominant clone relative to all infected cells is represented by longitudinal charts with colored dots corresponding to
each time point (diagnosis, relapse, complete remission CR1, CR2 and CR3). Pink area with red dots indicates the period of complete clinical
remission (Supplementary Table 1). Samples with a clonally rearranged TCR-γ gene have dots marked with a circle (TCR+). Clone frequency
distribution is illustrated by pie charts, each slice representing an independent integration site and its corresponding clonal abundance. The
dominant clone (relative abundance per 100 proviral copies, indicated below the pie chart) is depicted in red except for ATL11-Relapse-LN
(turquoise, clone switch) and ATL60 (four equally frequent proviruses in a single malignant clone, single TCR-γ rearrangement, Table 1). The
remaining underlying clones are shown in gray. PVL: proviral load (tax copies per 100 peripheral blood mononuclear cells (PBMCs)). Absolute
abundance (percentage of HTLV-1 insertion sites in PBMCs) was calculated from PVL and the clone’s relative abundance. Absolute abundance
of malignant integration sites at CR ATL14-CR1o0.007% (d, PVL: 0.016%, relative abundance within HTLV-1-infected PBMCs, 43%).
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upon progression and is superior to any conventional method
available thus far. The optimized protocol overcomes previous
limitations in terms of sensitivity, cost and hands-on time, facilitating
implementation in the clinic. Our data support its incorporation in
routine follow-up, providing clinicians with a tool to rapidly identify
patients who do not beneﬁt from standard therapy and should be
enrolled in alternative or novel upfront strategies. It is possible to
integrate this approach into next-generation sequencing-based
mutation proﬁling schemes that are increasingly used for monitor-
ing patients with hematological malignancies. As such, although
small scale, the study by itself provides a strong proof-of-concept to
build on and establishes the rationale for further clinical evaluation.
Efforts of the HTLV-1 community will be needed to deﬁne how HTS
clonality data should be reported for clinical utilization and delineate
the optimal time/interval for assessing molecular response in
standardized care.
Altogether, our observations highlight the great molecular
heterogeneity within patients who achieve complete clinical and
hematological remission, underlining the need for revisiting
response criteria for ATL. We propose this HTS approach as a
method to detect minimal residual disease, estimate graft-versus-
ATL effect after allogeneic stem cell transplantation and evaluate
clinical trials that remain critical to improving outcomes.
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